Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 25% during trading on Thursday . The company traded as high as C$0.36 and last traded at C$0.35. 1,444,856 shares traded hands during mid-day trading, an increase of 111% from the average session volume of 684,559 shares. The stock had previously closed at C$0.28.
Hemostemix Price Performance
The business has a fifty day moving average of C$0.12 and a 200 day moving average of C$0.09. The stock has a market capitalization of C$30.49 million, a price-to-earnings ratio of -17.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Dividend Capture Strategy: What You Need to Know
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Canada Bond Market Holiday: How to Invest and Trade
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Golden Cross Stocks: Pattern, Examples and Charts
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
